Escin inhibits lipopolysaccharide-induced inflammation in human periodontal             ligament cells.
Periodontitis is a chronic inflammatory disease associated with gram-negative             subgingival microflora infection. Accumulating experimental evidence suggests             that escin exerts anti-inflammatory and anti-edematous effects. This study was             designed to investigate the in vitro effects of escin on the inflammatory reaction             of human periodontal ligament cells (hPDLs). hPDLs were stimulated with lipopolysaccharide             (LPS). The cells were treated with various concentrations of escin. The viability             of hPDLs was evaluated using the MTT method. The expression of Toll-like receptor 2             (TLR2) in hPDLs and the levels of IL-1β, TNF-α and IL-6 in the supernatant were             measured. Escin significantly attenuated LPS-induced cytotoxicity in a concentration-dependent             manner in hPDLs. Treatment with escin partly blocked the expression of TLR2. Escin             also lowered the increase of pro-inflammatory cytokines (IL-1β, TNF-α and IL-6)             induced by LPS. The present findings show that escin exerts a protective effect             against LPS-induced inflammation in hPDLs. It was also shown that escin is a promising             medicine for the treatment of periodontitis.
Department of Periodontology, Yantai Stomatological Hospital, Binzhou Medical University, Yantai 264008, PR China.
Shutai
S
Liu
Huaizhou
H
Wang
Caiqing
C
Qiu
Jing
J
Zhang
Taowen
T
Zhang
Wenjuan
W
Zhou
Zhishan
Z
Lu
Xiaohui
X
Rausch-Fan
Zhonghao
Z
Liu
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D004928:Escin / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity; D010513:Periodontal Ligament / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010518:Periodontitis / Q000378:metabolism / Q000473:pathology; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D051195:Toll-Like Receptor 2; D014409:Tumor Necrosis Factor-alpha; D004928:Escin